Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 92.9%

Neg 0% Neu 0% Pos 92.9%

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.